title: Peripheral neuropathy exacerbated by lenalidomide in a patient with multiple myeloma.
abstract: We evaluated a serial change in peripheral neuropathy (PN) severity during treatment with bortezomib (Bor) or lenalidomide (Len) using the Functional Assessment of Cancer Therapy scale/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx). The patient suffered from grade 2 PN and exhibited a dramatic decrease in FACT/GOG-Ntx score after intravenous and subcutaneous Bor therapy. Thereafter, he received seven cycles of Len therapy, which exacerbated existing PN; he experienced mild numbness and exhibited a transient decrease in FACT/GOG-Ntx score. Interestingly, FACT/GOG-Ntx score increased to baseline and numbness was ameliorated during the Len washout period in every cycle.
authors.affiliation: Department of Hematology, Harasanshin Hospital, Japan.
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Kamimura
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Miyamoto
authors.forename: Noriko
authors.initials: N
authors.lastname: Yokota
authors.forename: Takatoshi
authors.initials: T
authors.lastname: Aoki
authors.forename: Yoshikiyo
authors.initials: Y
authors.lastname: Ito
authors.forename: Koichi
authors.initials: K
authors.lastname: Akashi
mesh_terms: D017809:Fatal Outcome; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use; D007866:Leg / Q000294:innervation; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000209:etiology; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D007155:Immunologic Factors; D013792:Thalidomide; D000077269:Lenalidomide